Fluticasone/Vilanterol
Brand name: Breo Ellipta
Rank #38 of 500 drugs by total cost
$493.0M
Total Cost
909,837
Total Claims
$493.0M
Total Cost
27,171
Prescribers
$542
Cost per Claim
115,425
Beneficiaries
1,196,222
30-Day Fills
$18K
Avg Cost/Provider
33
Avg Claims/Provider
About Fluticasone/Vilanterol
Fluticasone/Vilanterol (sold as Breo Ellipta) was prescribed 909,837 times by 27,171 Medicare Part D providers in 2023, costing the program $493.0M. At $542 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 35 | Fluticasone Propion/Salmeterol (Advair Diskus) | $523.2M | 1,289,942 |
| 36 | Varicella-Zoster Ge/As01b/Pf (Shingrix) | $514.4M | 2,419,884 |
| 37 | Tafamidis (Vyndamax) | $511.1M | 20,589 |
| 38 | Fluticasone/Vilanterol (Breo Ellipta) | $493.0M | 909,837 |
| 39 | Tiotropium Bromide (Spiriva Handihaler) | $478.1M | 673,800 |
| 40 | Evolocumab (Repatha Sureclick) | $460.5M | 528,560 |
| 41 | Acalabrutinib Maleate (Calquence) | $457.0M | 31,890 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology